TREE NEWS reports: More than 40 A-share pharmaceutical and biotech companies had disclosed third-quarter results by Oct. 22, with over 50% posting earnings growth, alongside additional companies issuing preliminary nine-month forecasts. The growth was supported by continued sales volume expansion of multiple products in end markets and by revenue recognition of upfront and milestone payments from outbound licensing deals.
Over Half of A-Share Pharma Firms Report Q3 Growth on Commercialization, Licensing Deals
AI take
The split between volume-led growth and licensing-driven revenue matters because the latter is lumpy and milestone-dependent, while the former signals durable end-market demand. For A-share pharma and biotech names, the key question is how much of reported growth rests on one-off upfront payments versus recurring product sales. Whether licensing revenue recognition sustains into coming quarters, and how preliminary nine-month forecasts from the remaining companies compare, is the open question worth tracking.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
13m ago
Paris extends curfew in parts of city until 6 a.m. October 25
14m ago
UK NAO warns HMRC risks losing £20.2bn in tax debt
15m ago
Samsung Electronics, SK Hynix fall at least 2.9% in Korea Nextrade premarket trading
18m ago
Over 200 A-Share Firms Report Q3 Results; More Than 60% Post Profit Growth
19m ago
China’s bank wealth products hit 35.37 trillion yuan at end of Q3 2026
20m ago
UK GfK Consumer Confidence Falls to -24 in October, Far Below Forecasts